Guangdong Marubi Biotechnology Co., Ltd.

SHSE:603983 Stock Report

Market Cap: CN¥12.8b

Guangdong Marubi Biotechnology Future Growth

Future criteria checks 5/6

Guangdong Marubi Biotechnology is forecast to grow earnings and revenue by 25.1% and 22% per annum respectively. EPS is expected to grow by 24.8% per annum. Return on equity is forecast to be 13.6% in 3 years.

Key information

25.1%

Earnings growth rate

24.8%

EPS growth rate

Personal Products earnings growth25.7%
Revenue growth rate22.0%
Future return on equity13.6%
Analyst coverage

Good

Last updated05 Feb 2025

Recent future growth updates

Recent updates

Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Dec 25
Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)

Dec 09
Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)

Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?

Nov 22
Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?

Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher

Sep 26
Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher

Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations

Aug 30
Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations

Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Jun 19
Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital

Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

May 29
Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet

Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?

May 07
Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?

Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion

Mar 27
Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion

Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around

Feb 29
Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around

Earnings and Revenue Growth Forecasts

SHSE:603983 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,34756856562713
12/31/20253,62145943059013
12/31/20242,90735617435013
9/30/20242,64132430339N/A
6/30/20242,51830546319N/A
3/31/20242,41029194374N/A
12/31/20232,22625984338N/A
9/30/20232,124228-36178N/A
6/30/20231,974188-93113N/A
3/31/20231,826187-3269N/A
12/31/20221,732174-6248N/A
9/30/20221,793226-25122N/A
6/30/20221,730176-7948N/A
3/31/20221,766213-147-13N/A
12/31/20211,787248-125-7N/A
9/30/20211,745268-62725N/A
6/30/20211,825385-519253N/A
3/31/20211,779446-434319N/A
12/31/20201,745464-387362N/A
9/30/20201,727494154327N/A
6/30/20201,780527309339N/A
3/31/20201,806514372400N/A
12/31/20191,801515459466N/A
9/30/20191,732539540544N/A
6/30/20191,662477557562N/A
3/31/20191,606440473481N/A
12/31/20181,576415505517N/A
12/31/20171,352312N/A356N/A
12/31/20161,208232N/A213N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603983's forecast earnings growth (25.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 603983's earnings (25.1% per year) are forecast to grow faster than the CN market (25.1% per year).

High Growth Earnings: 603983's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603983's revenue (22% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 603983's revenue (22% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603983's Return on Equity is forecast to be low in 3 years time (13.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 04:25
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guangdong Marubi Biotechnology Co., Ltd. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lei YangCGS International
Lei YangChina Galaxy International Securities (Hong Kong)
Weixuan ZhenChina Galaxy Securities Co., Ltd.